NBIX CSO sells 11,000 shares after option exercise
Neurocrine Biosciences Chief Scientific Officer Jude Onyia exercised options for 11,000 shares of common stock at $84.74 per share and, on the same day, sold 11,000 shares in open-market transactions at a weighted average price of $155.5332 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Neurocrine Biosciences Chief Scientific Officer Jude Onyia exercised options for 11,000 shares of common stock at $84.74 per share and, on the same day, sold 11,000 shares in open-market transactions at a weighted average price of $155.5332 per share.
The sale was carried out by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026. Following these transactions, Onyia directly holds 25,846 shares of common stock and 24,268 non-qualified stock options.
Insider Trade Summary 10b5-1
Exercise and Sale: 11,000 shares ($779K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Onyia Jude
Role
Chief Scientific Officer
Sold
11,000 shs ($1.71M)
Approx. gross sale proceeds
$1.71M
Approx. exercise cost
$932K
Approx. pre-tax spread
$779K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option | 11,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 11,000 | $84.74 | $932K |
| Sale | Common Stock | 11,000 | $155.5332 | $1.71M |
Holdings After Transaction:
Non-Qualified Stock Option — 24,268 contracts (Direct);
Common Stock — 25,846 shares (Direct)
Footnotes (4)
- F1. Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
- F2. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $154.47 to $156.74. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4. Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
Key Figures
Shares sold: 11,000 shares
Weighted average sale price: $155.5332 per share
Options exercised: 11,000 shares
+5 more
8 metrics
Shares sold
11,000 shares
Open-market sale on May 27, 2026
Weighted average sale price
$155.5332 per share
Common stock sold in multiple transactions
Options exercised
11,000 shares
Non-qualified stock option converted to common stock
Option exercise price
$84.74 per share
Strike price of non-qualified stock option
Common shares held after
25,846 shares
Direct ownership following transactions
Options remaining after
24,268 options
Non-qualified stock options outstanding after exercise
Option expiration date
November 29, 2031
Non-qualified stock option term
ESPP shares included
176 shares
Purchased on February 27, 2026 via 2018 ESPP
Key Terms
Rule 10b5-1 trading plan, Non-Qualified Stock Option, weighted average sales price, Employee Stock Purchase Plan, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option financial
"security_title: "Non-Qualified Stock Option""
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
weighted average sales price financial
"Represents a weighted average sales price per share. These shares were sold in multiple transactions"
Employee Stock Purchase Plan financial
"shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
vested and exercisable financial
"1/4th of the shares underlying the option became vested and exercisable on November 29, 2022"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did NBIX Chief Scientific Officer Jude Onyia report?
Jude Onyia reported exercising options for 11,000 Neurocrine Biosciences shares and selling 11,000 shares. The sale was an open-market transaction executed by a broker under a Rule 10b5-1 trading plan adopted earlier in 2026.
Were Jude Onyia’s NBIX stock sales made under a Rule 10b5-1 plan?
Yes, the disposition was executed under a Rule 10b5-1 trading plan adopted on February 25, 2026. The company’s policy restricts Onyia from amending or modifying this plan after adoption, indicating the sales were pre-arranged rather than opportunistic.
What stock option grant did Jude Onyia exercise in this NBIX Form 4?
Onyia exercised a non-qualified stock option covering 11,000 shares of common stock at an exercise price of $84.74 per share. The option began vesting on November 29, 2022, with monthly vesting thereafter, and is scheduled to expire on November 29, 2031.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates